First-line FOLFOX-4 ± cetuximab in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC): the open-label, randomize...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter S. Qin
Citation Annals of Oncology (2016) 27 (2): 1-3. 10.1093/annonc/mdw237
Authors S. Qin1, J. Xu2, L. Wang3, Y. Cheng4, T. Liu5, J. Chen6, S..P. Eggleton7, J. Liu6, J. Li8
  • 1Nanjing Bayi Hospital, Nanjing, China, /
  • 2307 Hospital of PLA, Beijing, China, /
  • 3Shanghai First People's Hospital, Shanghai, China, /
  • 4Jilin Cancer Hospital, Jilin, China, /
  • 5Zhongshan Hospital affiliated to Fudan University, Shanghai, China, /
  • 6Merck Serono, Beijing, China, /
  • 7Merck KGaA, Darmstadt, Germany, /
  • 8Fudan University Shanghai Cancer, Shanghai, China, /

Abstract

Cetuximab in combination with chemotherapy (either FOLFIRI or FOLFOX) is a standard-of-care first-line treatment for patients with RAS wt mCRC. The addition of cetuximab to first-line FOLFIRI or FOLFOX-4 has previously been shown to improve survival outcomes in patients with RAS wt mCRC in the randomized phase 3 CRYSTAL trial and the randomized phase 2 OPUS trial. The purpose of the randomized phase 3 TAILOR trial is to confirm the efficacy and safety of FOLFOX-4 plus cetuximab vs FOLFOX-4 in the first-line treatment of Chinese patients with RAS wt mCRC.